ArticleJournal of neuro-oncology2009
Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction.
Article in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction.Neurology(R) neuroimmunology & neuroinflammation · 2025Pooled it
- Chronic intestinal pseudo-obstruction in the course of systemic sclerosis successfully treated with intravenous immunoglobulins and rituximab.Reumatologia · 2025Article
- Paraneoplastic syndrome with intestinal pseudo-obstruction in a patient with small cell lung carcinoma: a case report and literature review.The Journal of international medical research · 2025Review
- Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review.Brain sciences · 2024Review
- Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review.Journal of neurology · 2022Review
- Enteric neuroplasticity and dysmotility in inflammatory disease: key players and possible therapeutic targets.American journal of physiology. Gastrointestinal and liver physiology · 2019Review
- Pain as a First Manifestation of Paraneoplastic Neuropathies: A Systematic Review and Meta-Analysis.Pain and therapy · 2017Review
- Article
- Immunotherapy Prospects for Painful Small-fiber Sensory Neuropathies and Ganglionopathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome.Clinical and experimental immunology · 2014Article
- Autoimmune Gastrointestinal Paralysis: Failure of Conventional Treatment without Immunomodulation.Case reports in surgery · 2014Article
- The great masquerader of malignancy: chronic intestinal pseudo-obstruction.Biomarker research · 2014Article
- Limbic encephalitis and related cortical syndromes.Current treatment options in neurology · 2013Article
- Paraneoplastic neurological syndromes: general treatment overview.Current treatment options in neurology · 2013Article
- Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction.Gastroenterology & hepatology · 2013Article
- A novel approach to paraneoplastic intestinal pseudo-obstruction.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Article
- Treatment of paraneoplastic neurologic disorders.Current treatment options in neurology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-Hu paraneoplastic syndromes are usually associated with an underlying neoplasia, although a few patients who are anti-Hu-positive never develop cancer after long-term follow-up. Tumour therapy remains the mainstay of therapeutic options, and early immune therapy in parallel is advisable. When no tumour is found, immunologically-based therapies are nowadays the only options. Recent studies have shown rituximab associated with the tumour therapy to be effective for some patients with anti-Hu paraneoplastic syndrome. We report a case of a patient with anti-Hu antibodies-associated sensory neuronopathy and gastric pseudo-obstruction without an underlying neoplasia four years after the first manifestation who has achieved sustained improvement for two years after treatment with rituximab. This case report supports the effectiveness of rituximab in these syndromes, even for cases where no underlying neoplasia is demonstrated. Further studies are warranted in order to confirm these preliminary data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.